May 8, 2022
Sam Lee, interim Co-CEO and President, and Jim Martin, interim Co-CEO and CFO of Cocrystal Pharma. They're a clinical stage biotech company using their proprietary drug development platform to create novel antiviral therapeutics to treat seasonal influenza and pandemic viral infections like COVID-19.
Jim explains, "There are vaccines, and then there are therapeutics. We are a therapeutic company. We don't produce vaccines. Vaccines are more preventative. What we do is, once you get the illness, we stop the illness through our compounds. So as a therapeutic, you do need that one-two punch of both vaccines and therapeutics. And in the case of influenza, we have every year people getting vaccines, which are good. But the therapeutics that are necessary are far and few between."
Sam elaborates, "So our compounds, the compound IDs of CC-42344, we're currently doing phase one study in Australia, this compound has an outstanding drug-resistant profile. We have not been able to isolate the drug-resistance strains from in vitro test-tube experiments. So we believe this compound is really designed for the pandemic as well as a seasonal treatment, particularly targeting for influenza A infection. And also, because of the excellent drug resistance profile, we believe this would be a real breakthrough influenza treatment for pandemic as well as seasonal infection."
@CocrystalPharma #Flu #Influenza #Pandemic #SeasonalFlu #COVID #Vaccines #COVIDTreatments #FluTreatments
